Bionik Laboratories Revenue Growth Rates (BNKL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Bionik Laboratories Corp   (BNKL)
 

BNKL's Revenue Growth by Quarter and Year

Bionik Laboratories 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BNKL Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter March 0.50
3rd Quarter December 0.58
2nd Quarter September 0.49
1st Quarter June 0.24
FY 1.81

BNKLs Annual Revenue
Bionik Laboratories 's Revenue in the fiscal year 2023 $ 1.81 millions
Bionik Laboratories 's Revenue in the fiscal year 2022 $ 1.27 millions
Bionik Laboratories 's Revenue in the fiscal year 2021 $ 1.19 millions
Bionik Laboratories 's Revenue in the fiscal year 2020 $ 2.15 millions
Bionik Laboratories 's Revenue in the fiscal year 2019 $ 3.25 millions




BNKL Revenue fourth quarter 2023 Y/Y Growth Comment
Bionik Laboratories Corp reported Revenue surge of 163.74% year on year in the fourth quarter 2023, to $ 0.50 millions, this is lower than Bionik Laboratories Corp 's recent average Revenue surge of 175.57%.

Looking into fourth quarter 2023 results within Medical Equipment & Supplies industry 11 other companies have achieved higher Revenue growth. While Bionik Laboratories Corp ' s Revenue doubling of 163.74% ranks overall at the positon no. 205 in the fourth quarter 2023.


BNKL Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter March 163.74 % -58.7 % -50 % -27.56 %
3rd Quarter December 222.22 % 0 % 12.5 % -82.8 %
2nd Quarter September 113.04 % -20.69 % 3.57 % -49.09 %
1st Quarter June -64.18 % 157.69 % -67.09 % 58 %
FY   42.61 % 6.72 % -44.65 % -

Financial Statements
Bionik Laboratories 's fourth quarter 2023 Revenue $ 0.50 millions BNKL's Income Statement
Bionik Laboratories 's fourth quarter 2022 Revenue $ 0.19 millions Quarterly BNKL's Income Statement


BNKL Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter March -13.6 % 5.56 % 155.56 % 475 %
3rd Quarter December 18.37 % -21.74 % -37.93 % -42.86 %
2nd Quarter September 104.17 % -65.67 % 11.54 % -64.56 %
1st Quarter June 26.32 % 45.65 % -71.74 % -37.8 %
FY (Year on Year)   42.61 % 6.72 % -44.65 % -


Back to BNKL Growth rate Comparisons >> Back to BNKL Growth rate Comparisons >>


Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #12
Healthcare Sector #58
Overall #205

Revenue Y/Y Growth Statistics
High Average Low
2347.08 % 175.57 % -92 %
(Mar 31 2018)   (Mar 31 2013)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #12
Healthcare Sector #58
Overall #205
Revenue Y/Y Growth Statistics
High Average Low
2347.08 % 175.57 % -92 %
(Mar 31 2018)   (Mar 31 2013)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Bionik Laboratories 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1937.01 % 121.62 % -95.42 %
(Dec 31 2016)  


BNKL's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 Bionik Laboratories Corp disclosed drop in Revenue from the third quarter by -13.6% to $ 0.50 millions, from $ 0.58 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2023 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Medical Equipment & Supplies industry 150 other companies have achieved higher Revenue quarter on quarter growth. While Bionik Laboratories 's Revenue growth quarter on quarter, overall rank is 3223.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #151
Healthcare Sector #493
Overall #3223
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #151
Healthcare Sector #493
Overall #3223
Revenue Q/Q Growth Statistics
High Average Low
1937.01 % 121.62 % -95.42 %
(Dec 31 2016)  


BNKL's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 Bionik Laboratories Corp disclosed drop in Revenue from the third quarter by -13.6% to $ 0.50 millions, from $ 0.58 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2023 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Medical Equipment & Supplies industry 150 other companies have achieved higher Revenue quarter on quarter growth. While Bionik Laboratories 's Revenue growth quarter on quarter, overall rank is 3223.


Bionik Laboratories 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)
Cumulative Revenue 12 Months Ending $ 1.81 $ 1.50 $ 1.11 $ 0.85 $ 1.28
Y / Y Revenue Growth (TTM) 41.41 % -3.04 % -28.26 % -47.22 % 6.97 %
Year on Year Revenue Growth Overall Ranking # 3015 # 2007 # 2388 # 1546 # 3031
Seqeuential Revenue Change (TTM) 20.49 % 35.41 % 30.45 % -33.56 % -17.38 %
Seq. Revenue Growth (TTM) Overall Ranking # 2619 # 1976 # 2671 # 3804 # 2532


Cumulative Revenue growth Comment
Although Bionik Laboratories 's Annual Revenue growth year on year were below company's average 47.67% , Revenue announced in the Mar 31 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 41.41% year on year, from -3.04% in Dec 31 2022.

In the Healthcare sector 430 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2007 to 3015.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 110
Healthcare Sector # 431
Overall # 3015

Revenue TTM Y/Y Growth Statistics
High Average Low
307.88 %
 47.67 %
-54.15 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 110
Sector # 364
S&P 500 # 2619
Cumulative Revenue growth Comment
Although Bionik Laboratories 's Annual Revenue growth year on year were below company's average 47.67% , Revenue announced in the Mar 31 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 41.41% year on year, from -3.04% in Dec 31 2022.

In the Healthcare sector 430 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2007 to 3015.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 110
Healthcare Sector # 431
Overall # 3015

Revenue TTM Y/Y Growth Statistics
High Average Low
307.88 %
47.67 %
-54.15 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 110
Sector # 364
S&P 500 # 2619




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BNKL's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Mar 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2023
Vbi Vaccines Inc284.92%$ 284.921 millions
Mersana Therapeutics inc 283.20%$ 283.202 millions
Scorpius Holdings inc 260.56%$ 260.563 millions
Cidara Therapeutics Inc 259.16%$ 259.155 millions
Clene Inc 256.67%$ 256.667 millions
Lipella Pharmaceuticals Inc 256.64%$ 256.640 millions
Mannkind Corporation238.78%$ 238.776 millions
Inmed Pharmaceuticals Inc233.96%$ 233.963 millions
Fate Therapeutics Inc 220.30%$ 220.300 millions
Apellis Pharmaceuticals Inc 211.84%$ 211.842 millions
Pavmed Inc 200.00%$ 200.000 millions
Uniqure N v 197.15%$ 197.154 millions
Roivant Sciences Ltd 196.82%$ 196.823 millions
Beam Therapeutics Inc 187.10%$ 187.097 millions
Aclarion Inc 182.18%$ 182.185 millions
Motus Gi Holdings Inc 180.00%$ 180.000 millions
Intra cellular Therapies Inc 172.33%$ 172.334 millions
Inovio Pharmaceuticals Inc 167.25%$ 167.251 millions
Precision Biosciences Inc164.70%$ 164.697 millions
Sera Prognostics Inc 163.16%$ 163.158 millions
Transmedics Group Inc 161.68%$ 161.675 millions
Cytomx Therapeutics Inc 159.94%$ 159.945 millions
Bionik Laboratories Corp 158.15%$ 158.153 millions
Whitehawk Therapeutics Inc 154.31%$ 154.313 millions
Quantum Cyber N v 148.70%$ 148.699 millions
Impel Pharmaceuticals Inc 148.55%$ 148.550 millions
Mirum Pharmaceuticals Inc 145.10%$ 145.098 millions
Eton Pharmaceuticals Inc 143.75%$ 143.750 millions
Intelligent Bio Solutions Inc 137.43%$ 137.433 millions
Lucid Diagnostics Inc 135.98%$ 135.979 millions


About Bionik Laboratories Revenue Growth Rates (BNKL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Bionik Laboratories Corp (CIK 1508381).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001410578-23-001453
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Bionik Laboratories Corp ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.